Sanofi-aventis invests to expand Beijing plant

By Ding Yining | April 22, 2009, Wednesday |

Print Edition

SANOFI-AVENTIS yesterday said it would inject US$90 million to expand its manufacturing facility in Beijing.

The world's fourth-biggest drug maker will see a significant increase in its output of the insulin medicine, Lantus SoloSTAR, after the expansion is completed in 2012.

This latest investment followed a US$94-million investment in Shenzhen in 2007 to establish a plant to produce Vaxigrip, a vaccine for influenza. The first phase of the project is now completed, and the production line will be operational in 2012.

"As the first multinational health-care company to establish an office in China, we remain convinced of the strategic importance of the Chinese market," said Christopher A. Viehbacher, CEO of Sanofi-aventis.

The two investments combined together make Sanofi-aventis the biggest investor in China's pharmaceutical field, according to the company.

China now has 40 million people suffering from diabetes, according to latest statistics by the International Diabetes Federation.

The French drug maker is also investing US$39.4 million to build a new facility in Hangzhou, capital of Zhejiang Province. The new factory is set to be completed by 2012.

Manufacturing

About Us
|
Terms of Use
|
RSS
|
Privacy Policy
|
Contact Us
|
Shanghai Call Center: 962288
|
Tip-off hotline: 52920043

沪ICP证：沪ICP备05050403号-1
|
互联网新闻信息服务许可证：31120180004
|
网络视听许可证：0909346
|
广播电视节目制作许可证：沪字第354号
|
增值电信业务经营许可证：沪B2-20120012

Sanofi-aventis invests to expand Beijing plant

Email this to your friend